Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs EHang Holdings Ltd - ADR (EH) Price & Performance

Quest Diagnostics IncTrade
EHang Holdings Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs EHang Holdings Ltd - ADR — how do they compare? Quest Diagnostics Inc trades at $237.88 (market cap $26.21B), while EHang Holdings Ltd - ADR trades at $5.68 (market cap $437.63M). The key difference: Quest Diagnostics Inc is far larger — about 59.9× EHang Holdings Ltd - ADR's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.

DGXEH
Market Cap
$26.21B$437.63M
Sector
HealthIndustrials
52-Week High
$238.50$19.44
52-Week Low
$173.49$4.90
Enterprise Value
$31.97B$376.84M
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.79, up 1.76% today, with a mixed technical signal (bullish overall, bearish moving averages). The company reported Q1 2026 revenue of $418M, flat year-over-year, but net income margin remains deeply negative at -77.56%. Recent news includes the EH216-S completing Central Asia's first pilotless eVTOL flight in Kazakhstan (GlobeNewsWire, August 10, 2026), highlighting operational progress amid financial challenges.

Outlook is cautious; the stock faces significant execution risk with persistent losses and high cash burn, but analyst consensus price target of $6.97 offers modest upside. Investment opportunity hinges on successful commercialization of eVTOL technology, while risks include intense competition, regulatory hurdles, and reliance on financing to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH